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Abstract: Blood platelets have important roles in haemostasis, where they quickly stop bleeding
in response to vascular damage. They have also recognised functions in thrombosis, immunity,
antimicrobal defense, cancer growth and metastasis, tumour angiogenesis, lymphangiogenesis,
inflammatory diseases, wound healing, liver regeneration and neurodegeneration. Their brief
life span in circulation is strictly controlled by intrinsic apoptosis, where the prosurvival Bcl-2
family protein, Bcl-xL, has a major role. Blood platelets are produced by large polyploid precursor
cells, megakaryocytes, residing mainly in the bone marrow. Together with Mcl-1, Bcl-xL regulates
megakaryocyte survival. This review describes megakaryocyte maturation and survival, platelet
production, platelet life span and diseases of abnormal platelet number with a focus on the role of
Bcl-xL during these processes.
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1. Platelets
Platelets are small (2–4 µm in diameter), anucleate blood cells with a characteristic discoid
shape. They have multiple functions and a life span of 7–10 days in human. They are produced by
megakaryocytes (MKs), mostly in the bone marrow. Around 1011 platelets are produced every day.
The main function of platelets is to participate in the physiological process of haemostasis, allowing
bleeding to stop at the site of an injury, while maintaining normal blood flow elsewhere in the circulation.
The inner surface of blood vessels is covered by endothelial cells that act as anticoagulant. After
a vessel injury, the subendothelial matrix is exposed to the blood and several components of the blood
will be allowed to interact with this matrix. Among these blood components are platelets. Platelets are
present at 150 to 400 millions per millilitre (mL) of blood. They express receptors on their cell surface,
but in a healthy blood vessel, and under normal blood flow, these receptors do not meet their ligands,
and platelets do not adhere to surfaces or to each other. However, when the subendothelial matrix is
exposed, the ligands for some of the platelet receptors are revealed and platelets adhere. The most
important pathways in platelet adhesion is through the binding of immobilised von Willebrand factor
(VWF) in the subendothelium to platelet GPIb-IX-V (CD42) and subendothelial collagen to platelet
GPVI. The binding of platelet receptors with their ligands leads to platelet activation, i.e., secretion
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of the content of their granules, production of thromboxane A2 and subsequent activation of other
local platelets, exposure of membrane phospholipids and induction of conformational changes of
the αIIbβ3 (CD41/CD61) receptors. These receptors, when activated, can bind the fibrinogen that
physiologically circulates in the blood. Activated platelets will thus aggregate with each other thanks
to bridges made of fibrinogen and activated αIIbβ3 receptors on the platelet surface. Within seconds,
a platelet plug will be formed allowing the bleeding to stop. This process is called primary haemostasis.
In parallel, another process occurs after exposure of tissue factor in the subendothelial matrix that
is called coagulation. Coagulation allows formation of fibrin that will stabilise the platelet clot (for
review see [1]).
Platelets also have other roles than participating in haemostasis. They have been shown to
be involved in immunity, antimicrobial defense [2], cancer growth and metastasis [3–5], tumour
angiogenesis [6], lymphangiogenesis [5,7], inflammatory diseases [8–10], wound healing [11], liver
regeneration [12] and neurodegeneration [13].
The spleen and the liver are the organs where aged platelets are destroyed, if they have not been
used for haemostasis after 10 days of life. Moreover, not all platelets are circulating in the blood flow,
but approximately 30% of the total platelet mass exists as an exchangeable pool residing in the spleen.
This explains why increased spleen mass (splenomegaly) can be associated with lower platelet count
and why absence of spleen (asplenia) is associated with increased platelet counts.
2. Regulation of Platelet Life Span by Apoptosis: Role of Bcl-xL
Intrinsic apoptosis is tightly controlled by the Bcl-2 family of proteins, functionally divided into
pro- and antiapoptotic proteins. Bak and Bax are the proapoptotic molecules that dictate cell fate.
Activation of Bak and Bax will cause irreversible damage to the mitochondrial outer membrane with
subsequent cytochrome c release, apoptosome assembly and caspase activation. In healthy cells,
the antiapoptotic members Bcl-xL, Bcl-2, Mcl-1, Bcl-w, A1 and Bcl-b [14] restrain Bak and Bax. In
response to cellular stress, a third group of Bcl-2 proteins, the BH3-only initiator proteins (Bim, Puma,
Bad, Noxa, Bik, Hrk and Bmf), can inhibit the prosurvival proteins and indirectly as well as directly
contribute to the activation of Bak and Bax [15–18]. The balance between pro- and antiapoptotic
members of the intrinsic apoptosis pathway varies depending on cell type.
In adults, Bcl-xL plays an essential survival function in platelets [19,20]. Platelets are a unique
model in terms of life span regulation because they mostly depend on only two antagonistic Bcl-2
family members, i.e., Bcl-xL for their survival and Bak for their death [19,21], when in circulation at
steady-state. However, in response to apoptotic triggers, such as pharmacological inhibition or genetic
deletion of Bcl-xL, not only Bak, but both Bak and Bax regulate platelet lifespan [19,22–24].
How Bcl-xL/Bak controls platelet life span has been under intense scrutiny: in 2007, the Kile
laboratory found mutations in Bcl-x that resulted in decreased platelet counts in mice due to shortened
platelet life span [19]. Conversely, Bak-deficient mice exhibited a marked augmentation in platelet count
due to increased platelet half-life [19,22]. Pharmacological inhibition of Bcl-xL causes thrombocytopenia
in mice and humans, first demonstrated with drugs such as navitoclax (ABT-263) and ABT 737 [19,20,25];
however, in addition to Bcl-xL, they also inhibited prosurvival Bcl-2 and Bcl-w.
Do other prosurvival Bcl-2 family members, in addition to Bcl-xL, contribute to the regulation of
platelet life span? There is compelling evidence that both human and murine platelets express Bcl-2
protein [19,20,22,26–32]. However, as pharmacological Bcl-2 inhibition [33,34] or specific deletion in
MKs and platelets [27] had no effect on platelet number and life span, Bcl-2 is unlikely to play a role in
the regulation of platelet life span. While Bcl-w has been shown to be present in platelets [20,28], it
is not likely to control platelet life span since systemic BCL2L2 knockout mice did not alter platelet
numbers [35,36]. It is currently unclear if A1 protein is present in platelets, but A1 RNA has been
detected in young human and murine platelets [37,38]. In mice, platelet counts were not changed by
systemic A1a knock out [39] and another study targeting all A1 isoforms did not report any alteration
of platelet counts [40]. The Mcl-1 protein has a short half-life in part as a result of fast proteosomal
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degradation. While Mcl-1 is critical for haematopoietic stem cells and multipotent haematopoietic
progenitors [41] (Figure 1), neither haematopoietic overexpression of Mcl-1 nor conditional deletion in
the platelet lineage affected platelet counts or platelet life span in mice [42–44]. Mcl-1 protein is present
in MKs, but absent in both human and murine platelets [19,20,22,28,42,43]. However, young platelets
could potentially express some Mcl-1 as it was detected in murine platelets following proteasome
inhibitor treatment in vivo [43]. As specified above, anuclear platelets can undergo intrinsic apoptosis;
however, their incapability to uphold Mcl-1 protein levels makes them different to most other cell
types, as they are dependent on prosurvival Bcl-xL only [45–48]. Our current knowledge is therefore
that platelet life span in vivo is dictated by the balance between prosurvival Bcl-xL and proapoptotic
Bak (Figure 1).
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Figure 1. Summary of megakaryopoiesis and current knowledge on the role of the Bcl-xL/Bak axis
during megakaryopoiesis. HSC: Hematopoietic Stem Cell. CMP: Common Myeloid Progenitor. MEP:
Megakaryocyte Erythroid progenitor. MKP: Megakaryocyte Progenitor.
To explain how platelets die, the hypothesis of a differential life span between Bcl-xL and Bak
was proposed under the name of the “molecular clock model” [19]: as platelets have limited capacity
to synthesise new proteins, if Bcl-xL has a shorter life span than Bak, then Bak molecules eventually
outnumber Bcl-xL and platelet apoptosis ensues (Figure 2). In further support, in vitro aged human
platelets at 37 ◦C exhibited Bcl-xL degradation [26]. However, in 2013 the Kile laboratory revised their
molecular clock model and showed that in vivo aged platelets and young ones contain the same amount
of Bcl-xL [49]. If, therefore, platelet in vivo apoptosis is not simply the result of Bcl-xL degradation
over time, two hypotheses remain on what triggers platelet apoptosis in vivo (Figure 2): (1) a direct
activation of Bak by an unknown factor or (2) the function of Bcl-xL is modified in aged platelets
that may induce a decreased inhibitory activity on Bak. Furthermore, studies have shown that cell
surface glycoproteins are modified in aged platelets leading to their recognition and clearance by liver
macrophages and hepatocytes [50,51]. Future studies are needed to determine if there is a link between
platelet age-dependent changes in glycosylation and platelet apoptosis or if these processes are distinct.
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In regard to the first hypothesis, Bak activation could occur by BH3-only pro-death proteins. So
far, only genetic deletion of Bad has shown an effect, although minor, on platelet life span [52], while
deletion of Bid and Bim [28] or Puma [38] had no impact. It therefore remains to be established whether
other BH3-only proteins play a critical role in induction of apoptosis in platelets. Moreover, the second
hypothesis remains to be tested, i.e., whether the activity of Bcl-xL is modified as platelets age, and
whether this modification would lead to impairment of proapoptotic Bak restriction by Bcl-xL. It may
be that the ubiquitine–proteasome system participates in this process, as platelets express standard
and immunoproteasome.
3. Megakaryopoiesis and Its Regulation
Platelets are produced by their precursors, MKs, in a process called megakaryopoiesis. This
differentiation process occurs mainly in the bone marrow, but recent murine data have described that
it may also occur in the extravascular space of the lungs [53]. The MK/platelet lineage is derived
from a haematopoietic stem cell (HSC), which gives rise to all haematopoietic lineages including
the lymphoid and myeloid lineages. This HSC is located at the top of the hierarchy and in the classical
model this HSC will progressively lose its self-renewal capacities, a property absolutely required for
an HSC and then after a multi stage process will commit to one lineage as the MK/Platelet lineage by
giving a restricted MK progenitor [54]. In this model, there is strong evidence that the MK lineage
derives from a bipotent erythroid/MK progenitor. Recent results also suggest that MK progenitors
can directly derive from the HSC and that some HSC are biased towards the MK/platelet lineage [55].
It has been suggested that up to 60% of the MKs arise directly from a MK-biased HSC [56]. The MK
progenitors are able to proliferate and will switch from mitosis to endomitosis, an incomplete mitosis
related to a failure in cytokinesis leading to a polyploid cell associated with an increase in cell size.
This polyploidisation leads to cells with a 2 N ploidy ranging from 2 N to 128 N, with a modal ploidy
at of 16 N [57]. Because platelets are formed from the MK cytoplasm, this process leads to a marked
amplification in platelet production. As soon as MK enters the polyploidisation process, it begins to
synthesise the main platelet proteins, such as αIIb, GPIb and VWF, and develop specific organelles
such as the demarcation membrane system (DMS), a highly tortuous invaginated membrane system
necessary for the formation of platelets.
The later stage of megakaryopoiesis is often referred to as proplatelet formation. It corresponds
to the stage when usually large polyploid MKs shed long-branching cytoplasmic protrusions called
proplatelets into the sinusoidal blood vessels from the bone marrow [58]. These proplatelets arise
from the DMS, unwinding the DMS under the driver forces of the cytoskeleton. With the shear
stress in blood flow, proplatelet fragments are teared off and will fragment into platelets in the blood
stream [59]. However, a recent 2020 study by Potts et al., proposes that MK membrane budding, rather
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than proplatelet formation, supplies the majority of the platelet biomass without induction of cell
death [60]. Even so, platelets are small cytoplasmic fragments of MK cytoplasm, devoid of nucleus and
able of residual protein synthesis due to the presence of mRNA coming from the MK. Alternatively,
entire MK may migrate in the blood flow where they could be fragmented predominantly in the small
lung vessels.
Thrombopoietin (TPO) is the main extrinsic regulator of platelet production [61] and binds
to its cognate receptor, called MPL, which is a type 1 homodimeric cytokine receptor. Binding of
TPO to MPL induces signalling through JAK2 and then downstream effectors such as STAT5, which
regulates Bcl-xL expression [62,63]. In humans, homozygous loss of function mutations of MPL or
TPO leads to a profound thrombocytopenia followed by an aplastic anemia, underscoring the role of
the TPO/MPL axis in platelet production. TPO behaves as a hormone and is mainly synthesised by
the liver. The regulation of the TPO plasma level is mainly, but not uniquely, regulated by its clearance.
Indeed, platelets express MPL, bind TPO, and then TPO is endocytosed and degraded by platelets
inversely correlating the blood TPO and platelet levels [64].
Intrinsically, MK differentiation is regulated by several transcription factors that can be in the same
transcriptional large complex. The most important transcription factors are GATA1, RUNX1, FLI-1,
GFI-1b and TAL1/SCL, some of them such as GATA1 regulating Bcl-xL expression. The transcription
factor NF-E2 is involved in late stages of differentiation [65].
4. Diseases of Platelet Numbers in Humans
The normal platelet count ranges from 150 to 400 × 106 per mL in humans. The platelet level
is affected in numerous diseases and can increase over 400 × 106/mL (thrombocytosis) or decrease
to less than 150 × 106/mL (thrombocytopenia). Platelet disorders can be totally indolent. Indeed,
thrombocytopenia leads to spontaneous bleeding only when the platelet number is less than 30 ×
106/mL. On the contrary, thrombocytosis, in certain settings, can be associated with thrombosis, but
the risk of thrombosis is not correlated with the number of platelets. Therefore, routine screening
identifies many patients with asymptomatic thrombocytosis or thrombocytopenia.
4.1. Thrombocytosis (Platelet Count over 400 × 106/mL)
Most thrombocytosis (over than 90%) are reactive and secondary to infection or inflammatory
diseases (autoimmune, cancer and tissue injury) as inflammatory cytokines increase platelet production
directly or indirectly by increasing TPO synthesis (Table 1). Iron deficiency can also lead to moderate
thrombocytosis, or even thrombocytopenia when the iron deficiency is severe. The precise mechanism
is unknown although it has been suggested that iron deficiency induces a bias towards MK commitment
of a bipotent erythroid/MK progenitor [66]. Another setting associated with reactive thrombocytosis is
when the spleen has been removed (splenectomy) or is not functional (asplenism).
Table 1. Causes of thrombocytosis in human.
Primitive
Acquired:
- Myeloproliferative Neoplasms (Essential thrombocytopenia, Polycythemia Vera, Primitive Myelofibrosis,
Chronic Myeloid Leukemia)
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Non-reactive thrombocytosis can be either inherited or clonal. In this latter case, they are due to
the acquisition of somatic mutations in a haematopoietic stem cell, giving rise to myeloproliferative
neoplasms (MPN) or myeloproliferative/myelodysplastic disease. Interestingly, whether they are
inherited or acquired they are related to abnormalities in the TPO/MPL/JAK2 axis [62]. Inherited
thrombocytosis are very rare. They can be due to mutations in the TPO gene (with increased TPO
production), MPL (with a defect in TPO clearance), and rarely of JAK2. However, there also some
unexplained inherited thrombocytosis.
Acquired, clonal thrombocytosis is mainly found in BCR-ABL-negative MPN. This disease includes
three disorders, polycythemia vera, essential thrombocythemia and primary myelofibrosis, which are
characterised by increased blood cell production. Most of them are driven by mutations in three genes:
JAK2 (JAK2V617F), CALR (calreticulin) and MPL [67]. All these mutations induce a constitutive
activation of the MPL/JAK2 axis, and thus increased expression of Bcl-xL [68]. Nevertheless,
the molecular origin of 10% to 20% of essential thrombocythemia and primary myelofibrosis is
still unknown; these are called triple-negative MPN (JAK2V617F-CalR- and MPL-negative). Given
the common clinical and biological features between JAK2V617F and triple-negative MPN, it is very
probable that the same common signalling pathways are activated, i.e., the MPL/JAK2 axis [67].
4.2. Thrombocytopenia (Platelet Count Less Than 150 × 106/mL)
Thrombocytopenias are frequent, but in most cases they are not isolated but rather associate with
acute or complex pathologies. They are related either to a defect in platelet production, increased
platelet destruction or consumption, abnormal pooling or eventually to mixed mechanisms (Table 2).
Thrombocytopenia can be acute or chronic, acquired or inherited as reviewed recently [69].
Table 2. Causes of thrombocytopenia in human.
Due to defective platelet production
Acquired:
- Bone marrow infiltration (by malignant cells in most cases)
- Vitamin deficiency (B12, folates)
- Defect in megakaryocyte differentiation (myelodysplastic syndromes)
Constitutional (inherited) thrombocytopenia
- Absence of megakaryocytes
- Defects in megakaryocyte differentiation (mutations in transcription factors)
- Defects in proplatelet formation
Due to increased platelet destruction
Immunological processes
- Immune Thrombocytopenia Purpura
- Drug-induced thrombocytopenia
Non-Immunological processes: platelet consumption
- Microangiopathies (including thrombotic thrombocytopenia)
- Large hemorrhages
- Disseminated intravascular coagulation
- Sepsis
Secondary to abnormal pooling (hypersplenism due to splenomegaly)
4.2.1. Thrombocytopenia with Abnormal Pooling
They are the consequence of increased spleen sequestration (hypersplenism) that can occur when
the spleen is enlarged (splenomegaly).
4.2.2. Thrombocytopenia due to Defective Platelet Production
Thrombocytopenias that are related to a defect in platelet production are mostly the consequences of
a bone marrow infiltration, most often due to the proliferation of malignant cells, such as leukemic cells or
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cancer cells. They are thus most often associated with diminution of other blood cell types (i.e., anaemia
and leukopenia). They can also be the consequence of a defect in MK differentiation. That is observed
in myelodysplastic syndrome, vitamin B12 or folate deficiency. Here again, the thrombocytopenia is
rarely isolated.
Thrombocytopenias related to a defect in platelet production are frequently observed in inherited
thrombocytopenia [70]. These latter are due to various defects: (i) nearly absence of MKs in the rare
cases of MPL or TPO mutations; (ii) defects in MK differentiation due to mutations in transcription
factors (FLI1, RUNX1, GATA1, ETV6, IKZF5); and (iii) defects in proplatelet formation due to mutations
in genes coding for proteins involved in the cytoskeleton such as GPIB, Filamin A, MYH9, Actinin B,
and DIAPH1. The latter are frequently characterised by macrothrombocytopenia. However, even if
inherited thrombocytopenias are increasingly understood, the molecular basis is still unknown for
a significant number of patients.
4.2.3. Thrombocytopenia due to Increased Platelet Destruction or Consumption
Thrombocytopenias due to increased platelet destruction are heterogeneous disorders. They
include immunological and non-immunological processes. Non-immunological processes of platelet
destruction are mostly due to platelet consumption as in (i) microangiopathies, which are associated
with anemia and schizocytes; (ii) large haemorrhages; (iii) disseminated intravascular coagulation;
and (iv) sepsis due to viral or bacterial infections. Immunological mechanisms of platelet destruction
are mostly due to an autoimmune process called immune thrombocytopenia purpura (ITP) [71].
It is usually related to auto-antibodies directed against the main platelets glycoproteins αIIbβ3 or
GPIb-IX-V. This immune process is usually idiopathic, but can be also secondary to some autoimmune
disorders such as systemic lupus erythematosus, lymphoproliferative diseases or immune deficiency.
The thrombocytopenia is related to enhanced platelet destruction in the spleen and/or the liver and
therefore a very short platelet life span. However, a defect in platelet production is also frequently
observed. It is presumably related to an immune destruction of MKs in the bone marrow. The main
diagnostic problem of ITP is that the current techniques to detect anti-platelet antibodies are not
sensitive or specific enough. Thus, ITP remains a diagnosis of exclusion.
Thus, it is likely that a part of what is diagnosed as ITP, and more particularly ITP that are
resistant to steroid therapy or immune suppression, is actually not related to an immune process.
It is clear that some inherited thrombocytopenias are misdiagnosed as ITP. However, the diagnosis
will be facilitated by the development of Next-Generation Sequencing targeted on genes involved in
inherited thrombocytopenia. Furthermore, there are patients with acquired chronic thrombocytopenias
who are diagnosed with ITP, but do not have any immunological features but rather a real defect
in MK differentiation. It is possible that these patients do not have an immune disease, but rather
a haematological malignancy. It is conceivable that at least some of these patients can have an acquired
defect in MK differentiation and/or a short platelet life span. In these cases, the phenotype (bone
marrow aspiration, measurement of platelet life span) could be close to what is observed in typical ITP.
5. Role of Bcl-xL in Megakaryocyte Survival
Most of the data available on the role of Bcl-xL in MK life span have been obtained in mice. Similar
to platelets, MK survival is regulated by Bcl-xL, but a major difference is that they also depend on
prosurvival Mcl-1 (Figure 1). Cultured murine mature MKs were shown to undergo apoptosis and
failed to produce proplatelets after genetic loss of BCL2L1 gene (Bcl2-like1 or Bcl-x), or in response to
pharmacological Bcl-xL inhibition [22]. In mice, deletion of BCL2L1 in the MK lineage led to severe
macrothrombocytopenia, associated with the release of abnormal vacuolar fragments in the bone
marrow sinusoids [22]. It is therefore likely that MKs at the latest stage of their maturation process
depend on Bcl-xL in order to properly progress through the process of platelet release. Nevertheless,
in vivo loss of Bcl-xL did not negatively alter growth and maturation of MKs [22]. This finding
suggested redundancy with other pro-survival proteins, and strikingly, genetic dual loss of Mcl-1 and
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BCL2L1 in the MK lineage resulted in pre-weaning death [42,43]. Importantly, megakaryopoiesis was
negatively affected in BCL2L1/Mcl-1-deficient E12.5 embryos, with fewer and smaller MKs than normal
and the presence of haemorrhage. Besides, treatment of adult mice lacking Mcl-1 in the MK lineage
with Bcl-xL inhibitor (ABT-737) triggered MK apoptosis in vivo [42], with a rapid drop in MK and
platelet numbers. In summary, these studies revealed that prosurvival Bcl-xL and Mcl-1 are critical for
the survival of the MK lineage (Figure 1).
Data on the role of Bcl-xL in human megakaryopoiesis are at present unclear. Contrary to mouse
data, some studies have suggested that the intrinsic apoptotic pathway is required for proplatelet
formation, with “regional” rather than “whole-cell” death facilitating the necessary cytoskeletal
rearrangements. (i) Treatment of human MKs with the pancaspase inhibitor zVad blocked proplatelet
formation [72,73]. (ii) Retroviral overexpression of Bcl-2 in human cells leads to impaired proplatelet
formation [73]. (iii) A thrombocytopenic family with an activating mutation of cytochrome c was
shown to have increased differentiation of MKs with an abnormal release of the platelets in the bone
marrow [74]. Furthermore, a second mutation of cytochrome c was identified in an Italian family with
impaired thrombopoiesis [75]. It was reported that the two mutations in cytochrome c affected both
apoptosis and cellular bioenergetics [75,76] suggesting a potentially complex mechanism underlying
cytochrome c mutation and its effects on MK maturation and platelet production. Moreover, a recent
murine study has challenged the impact of proplatelet formation in vivo, where MK membrane
budding, rather than proplatelet formation was shown to supply the majority of the platelet biomass
without induction of cell death [60]. Thus, future studies are needed to gain mechanistic insights
into how the described conditions influence platelet production. A recent paper reported a major
role for Bcl-xL in human erythropoieisis and hematopoietic stem cells [77]; they also reported that
Bcl-xL knockdown negatively impacted human megakaryocyte survival, albeit not significantly.
Our unpublished results confirm that Bcl-xL knockdown impair human megakaryocyte survival, at
early and later stages of their differentiation (personal data). It can therefore not be excluded that
defects in Bcl-xL expression in human MKs could be responsible for unexplained thrombocytopenia
or thrombocytosis.
6. Conclusions
In summary, the platelet life span in circulation is strictly controlled by a balance between
prosurvival Bcl-xL and pro-death Bak and Bax. But the trigger of this pathway during platelet in vivo
ageing is yet to be defined. Murine studies show that MK survival is regulated by Mcl-1 and Bcl-xL.
Future studies are needed to investigate the role of Bcl-xL in human megakaryopoiesis.
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